Mitochondria-mediated pyroptosis: anti-glioblastoma mechanism of the frankincense-derived compound β-boswellic acid
- 3 Biotech. 2026 Feb;16(2):73. doi: 10.1007/s13205-025-04691-x.
- 1. Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210008 Jiangsu China.
- 2. The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007 Hunan China.
- 3. Changsha Medical University, Changsha, 410219 Hunan China.
- 4. Hunan University of Chinese Medicine, Changsha, 410208 Hunan China.
- 5. Hunan Academy of Chinese Medicine, Changsha, 410013 Hunan China.
This study aimed to investigate the antitumor effects and underlying mechanisms of β-boswellic acid (β-BA) in glioblastoma (GBM). U251 and U87 cells were treated with β-BA, and cell growth, migration/invasion, Pyroptosis, and mitochondrial function were evaluated using viability, proliferation, LDH release, immunofluorescence, ultrastructure, and Western blot assays. In vivo efficacy was assessed in a U251 xenograft mouse model. β-BA significantly inhibited GBM cell proliferation, migration, and invasion in a dose-dependent manner. β-BA induced mitochondrial structural disruption, loss of mitochondrial membrane potential, and excessive ROS accumulation, which activated the NLRP3 inflammasome and triggered Pyroptosis, as evidenced by elevated cleaved Caspase-1, GSDMD-N, and ASC expression. MCC950 partially reversed these effects, confirming NLRP3 involvement. In vivo, β-BA markedly reduced tumor growth and consistently induced mitochondrial damage, NLRP3 activation, Pyroptosis execution, decreased Ki-67/PCNA levels, and suppression of EMT progression. β-BA exerts potent anti-GBM activity by inducing mitochondrial dysfunction and NLRP3-mediated Pyroptosis, providing a mechanistic basis for developing β-BA as a promising natural therapeutic candidate for GBM.
Supplementary information: The online version contains supplementary material available at 10.1007/s13205-025-04691-x.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer
-
target: NOD-like Receptor (NLR)Research Areas: Inflammation/Immunology
-
Research Areas: Cancer